Dr. Tolar is the founder, president, and CEO of Alzheon. Before founding Alzheon in June 2013, he held executive positions in several life sciences companies, including President and CEO of Knome, President and CEO of NormOxys, and Chief Scientific Officer and Chief Business Officer at CoMentis, where he established and grew new business areas and product opportunities. Dr. Tolar held a variety of clinical development and business leadership positions at Pfizer, where he was instrumental in a wide range of business transactions. In 2021, Dr. Tolar founded the International Neurodegenerative Disorders Research Center, INDRC, a global institute applying artificial intelligence and machine learning solutions to identify and validate therapeutic interventions for Alzheimer’s disease and other neurodegenerative disorders. He serves as the Chairman of the INDRC Executive Board. Dr. Tolar serves on business and scientific boards, including the Alzheimer’s Drug Discovery Foundation, the Alzheimer Foundation, the CERGE-EI Foundation, and Advance Healthcare Management Institute. During his academic career, Dr. Tolar was an assistant professor in the Department of Neurology at Yale University School of Medicine, where he focused on movement disorders. Dr. Tolar trained in neurology at Boston Medical Center, received a Ph.D. in Neuroscience for his work on the role of apolipoprotein E in the pathogenesis of Alzheimer’s disease, and received his M.D. from Charles University in Prague.
Dr. Tolar is the founder, president, and CEO of Alzheon. Before founding Alzheon in June 2013, he held executive positions in several life sciences companies, including President and CEO of Knome, President and CEO of NormOxys, and Chief Scientific Officer and Chief Business Officer at CoMentis, where he established and grew new business areas and product opportunities. Dr. Tolar held a variety of clinical development and business leadership positions at Pfizer, where he was instrumental in a wide range of business transactions. In 2021, Dr. Tolar founded the International Neurodegenerative Disorders Research Center, INDRC, a global institute applying artificial intelligence and machine learning solutions to identify and validate therapeutic interventions for Alzheimer’s disease and other neurodegenerative disorders. He serves as the Chairman of the INDRC Executive Board. Dr. Tolar serves on business and scientific boards, including the Alzheimer’s Drug Discovery Foundation, the Alzheimer Foundation, the CERGE-EI Foundation, and Advance Healthcare Management Institute. During his academic career, Dr. Tolar was an assistant professor in the Department of Neurology at Yale University School of Medicine, where he focused on movement disorders. Dr. Tolar trained in neurology at Boston Medical Center, received a Ph.D. in Neuroscience for his work on the role of apolipoprotein E in the pathogenesis of Alzheimer’s disease, and received his M.D. from Charles University in Prague.